Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists
Author:
Affiliation:
1. University of Oxford
2. Charité Universitätsmedizin Berlin
3. Yale University
4. Johns Hopkins University School of Medicine
5. National University of Singapore
6. Murdoch Children’s Research Institute
7. University of Granada
Funder
Yale Institutional Review Board
Publisher
Informa UK Limited
Link
https://www.tandfonline.com/doi/pdf/10.1080/21507740.2024.2303154
Reference36 articles.
1. A Survey of American Psychiatrists' Attitudes Toward Classic Hallucinogens
2. Psychedelics: Where we are now, why we got here, what we must do
3. Empirical Support for the Moral Salience of the Therapy-Enhancement Distinction in the Debate Over Cognitive, Affective and Social Enhancement
4. Trial of Psilocybin versus Escitalopram for Depression
5. Valuing the acute subjective experience;Cheung K.;Perspectives in Biology and Medicine,2024
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon;Cancers;2024-04-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3